All In Biotech

NDA 215092 · Ocuvex Therap

Omlonti

Omidenepag Isopropyl · Ophthalmic

Novel

CDER novel approval, Sep 22, 2022: To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension

Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 22, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

66

64 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2025.

Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Therapeutic areas: Cardiovascular and metabolic · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 22, 2022 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • OMLONTI · OMIDENEPAG ISOPROPYL 0.002% · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omidenepag Isopropyl" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cataract20
  • contraindicated product administered9
  • intercepted product prescribing error6
  • cystoid macular oedema5
  • intraocular pressure increased5
  • anaphylactic reaction4
  • glaucoma4
  • macular oedema4
  • uveitis4
  • vision blurred4
  • ocular hyperaemia3
  • refraction disorder3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20221
202312
202421
202518
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Ocuvex Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.